Navigation Links
Pharmaceutical and Health Care Experts to Detail Cost-Cutting Capabilities of Secure Digital Signatures
Date:12/16/2008

2.gotomeeting.com/register/792964500" target="_new">https://www2.gotomeeting.com/register/792964500

The webinar will include a brief demonstration of digital signatures using TriCipher's MySignatureBook with SAFE-BioPharma credentials. For more information on MySignatureBook and the webinar, please visit http://www.Tricipher.com.

About TriCipher

TriCipher, Inc. provides a unified authentication infrastructure to protect web and enterprise portals, the people that use them and the business process that flows through them against fraud and identity theft. The TriCipher Armored Credential System(TM) (TACS) is the first authentication system that enables companies to deploy and manage multiple types of credentials from a single infrastructure. Through this flexible "Authentication Ladder," TriCipher protects customer investment by adjusting authentication strength to defeat new threats and to meet regulatory changes without the need to implement a new infrastructure. Recently, TriCipher introduced myOneLogin(TM) the first secure on-demand offering that delivers strong authentication, single sign-on (SSO) convenience and the ability to seamlessly integrate multiple Software as a Service (SaaS) applications in a single solution. Founded in 2000, TriCipher is headquartered in Los Gatos, Calif. The company is funded by ArrowPath Venture Capital, EPIC Ventures, Intel Capital, RBC Technology Ventures, and Trident Capital. For more information, visit TriCipher on the web at http://www.tricipher.com.

About MySignatureBook

TriCipher MySignatureBook(TM) is a web-based digital signing solution that gathers multiple signatures from a centrally managed, Web-based workflow to a single, unaltered document. MySignatureBook ensur
'/>"/>

SOURCE TriCipher, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)NEW ORLEANS, Dec. 5 There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in orde
(Date:12/5/2009)CAPE TOWN, South Africa, December 5 The first Football,for Hope Centre in Khayelitsha in the outskirts of Cape Town opened its doors,today (5 December 2009). FIFA President Joseph S. Blatter was join
(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int
(Date:12/5/2009)Research debunks the ,something,s wrong with being single, myth , , SATURDAY, Dec. 5 (HealthDay News) -- Pity the poor single people who pass their 40th birthday without ever tying the knot, s
(Date:12/5/2009)AVIVA today announced the launch of International Solutions, an innovative new international private medical insurance plan which follows the acclaimed modular design of its UK equivalent. In addition
Breaking Medicine News(10 mins):Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:AVIVA's Private Health Insurance Products Solutions Go International 2
...anuts and have an allergic response has dropped si...dations that at-risk families avoid exposing child...e, according to research led by a Childrens Hospit...ure and reaction were 14 and 18 months, respective...
... calls may be an effective, low-cost way to encour...ecent study by researchers at the Stanford Univers... study found that regular telephone calls delivere...e program. , What most surprised researchers was ...
...in preventing tooth decay have been known for over... of Americans have access to fluoridated public wa...the Indiana University School of Dentistry, Indian...at older adults benefit even more significantly fr...
... Agency Region 5 has awarded a $55,000 grant to th...oalitions in Cleveland and,Toledo to promote healt...., The coalitions are the Greater Cleveland Asthm... work to improve,conditions for asthma sufferers.,...
...E: AFL ) announced today that it will make a pres...ces CEO Conference. President and Chief,Financial ...ncorporated,and he is scheduled to make a presenta...7 and its strategy for growth in,the U.S. and Japa...
...ast Cancer Test MammaPrint(R), AMSTERDAM, the Net...w Dutch breast cancer test as one of the best inve...all" (MammaPrint(R)) invented and,developed by the...roviding hope to all women who have been,diagnosed...
Other Medicine News:Health News:Research finds allergic children exposed to peanuts at younger ages despite recommendations to avoid 2Health News:Computer calls can talk couch potatoes into walking, Stanford study finds 2Health News:Computer calls can talk couch potatoes into walking, Stanford study finds 3Health News:Aflac Incorporated to Present at the Goldman Sachs Financial Services CEO Conference 2007 2Health News:Time Magazine Names Agendia Test a Best Invention of 2007 2
(Date:12/4/2009)FREMONT, Calif., Dec. 4 Vermillion, Inc. (VRML) (Pink Sheets: VRMLQ) announced that on December 3, 2009, it filed its First Amended Plan of Reorganization and related amended Disclosure Statement wit
(Date:12/4/2009)EMERYVILLE, Calif., Dec. 4 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that it will host an investor teleconference and webcast. Principal investigators will discuss the data present
(Date:12/4/2009)STREAMWOOD, Ill., Dec. 4 Shared Imaging, LLC, an independent provider of CT, MRI and PET/CT systems and service programs for hospitals and healthcare providers, is excited to announce it has received
Breaking Medicine Technology:Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2Mpex Reports Positive Phase II Results with Aeroquin Delivered by PARI Pharmas eFlow Technology 57095 1Mpex Reports Positive Phase II Results with Aeroquin Delivered by PARI Pharmas eFlow Technology 57095 2Mpex Reports Positive Phase II Results with Aeroquin Delivered by PARI Pharmas eFlow Technology 57095 3Diabetes Drug Kills Cancer Stem Cells in Combination Treatment in Mice 57092 1Diabetes Drug Kills Cancer Stem Cells in Combination Treatment in Mice 57092 2Diabetes Drug Kills Cancer Stem Cells in Combination Treatment in Mice 57092 3Diabetes Drug Kills Cancer Stem Cells in Combination Treatment in Mice 57092 4Diabetes Drug Kills Cancer Stem Cells in Combination Treatment in Mice 57092 5Video 3A Seventh Annual Avon Walk for Breast Cancer Los Angeles Raises More Than 244 6 Million 57088 1Video 3A Seventh Annual Avon Walk for Breast Cancer Los Angeles Raises More Than 244 6 Million 57088 2Video 3A Seventh Annual Avon Walk for Breast Cancer Los Angeles Raises More Than 244 6 Million 57088 3Video 3A Seventh Annual Avon Walk for Breast Cancer Los Angeles Raises More Than 244 6 Million 57088 4Video 3A Seventh Annual Avon Walk for Breast Cancer Los Angeles Raises More Than 244 6 Million 57088 5
...ext Stage of Phase 2 Trial Achieved, SOUTH SAN FR...3:30 P.M. EDT, TODAY/ -- Sunesis Pharmaceuticals, ...eutical company developing novel,anticancer therap...ts from,the first stage of the company,s ongoing P...e, SNS-595, in platinum-resistant ovarian cancer p...
...t. 23 Boston,Scientific Corporation (NYSE: BSX )...its CABERNET and BEACH carotid artery stenting cli...ess of stenting with embolic,protection for patien...the,surgical treatment for carotid artery disease....esented by L. Nelson Hopkins, M.D., Chairman of,Ne...
Other Medicine Technology:Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference 2Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference 3Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference 4Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference 5Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results 2Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results 3Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results 4Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results 5
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
Medicine Products: